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Aminoacyl-tRNA synthetases (ARSs) are ubiquitously expressed enzymes that ligate amino acids
onto tRNAmolecules. Genes encoding ARSs have been implicated in phenotypically diverse dom-
inant and recessive human diseases. The charging of tRNAPHE with phenylalanine is performed
by a tetrameric enzyme that contains two alpha (FARSA) and two beta (FARSB) subunits. To date,
mutations in thegenesencoding these subunits (FARSAandFARSB) havenotbeen implicated in any
humandisease. Here,we describe a patientwith a severe, lethal, multisystem, developmental phe-
notypewhowas compoundheterozygous for FARSB variants: p.Thr256Met andp.His496Lysfs*14.
Expression studies using fibroblasts isolated from the proband revealed a severe depletion of
both FARSB and FARSA protein levels. These data indicate that the FARSB variants destabilize
total phenylalanyl-tRNA synthetase levels, thus causing a loss-of-function effect. Importantly, our
patient shows strong phenotypic overlap with patients that have recessive diseases associated
with otherARS loci; these observations strongly support the pathogenicity of the identified FARSB
variants and are consistentwith the essential function of phenylalanyl-tRNA synthetase in human
cells. In sum, our clinical, genetic, and functional analyses revealed the first FARSB variants associ-
ated with a human disease phenotype and expand the locus heterogeneity of ARS-related human
disease.
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Aminoacyl-tRNA synthetases (ARSs) are ubiquitously expressed
enzymes that ligate tRNA molecules to cognate amino acids, which
is the first step of protein translation (Antonellis & Green, 2008).
Unsurprisingly, ablation of the function of any ARS enzyme in species
ranging frommammals to bacteria is lethal, underscoring the essential
role of these enzymes in cellular life. The human nuclear genome
contains 37 ARS-encoding loci, which together encode 17 enzymes
required for tRNA charging in the mitochondria, 17 enzymes required
for tRNA charging in the cytoplasm, and three enzymes that charge
tRNA in both cellular compartments (Antonellis & Green, 2008).
ARS enzymes are named according to the single-letter code of the
amino acid they recognize followed by “ARS” and a variable “2” for
834 c© 2018Wiley Periodicals, Inc. HumanMutation. 2018;39:834–840.wileyonlinelibrary.com/journal/humu
ANTONELLIS ET AL. 835
mitochondrial enzymes. For example, cytoplasmic tyrosyl-tRNA
synthetase is referred to as “YARS,” whereas the corresponding
mitochondrial enzyme is referred to as “YARS2” (Antonellis & Green,
2008).
To date, 31 ARS loci have been implicated in dominant and reces-
sive human disease phenotypes (Meyer-Schuman & Antonellis, 2017).
First, each of the 17 ARS loci encoding a mitochondrial enzyme has
been implicated in recessive diseases and the vast majority are con-
sistent with stereotypical mitochondrial disease phenotypes. Second,
13 of the 20 ARS loci encoding a cytoplasmic or bifunctional enzyme
have been implicated in severe, early onset, developmental pheno-
types with mostly overlapping features (Meyer-Schuman & Antonellis,
2017). Finally, five ARS loci encoding either a cytoplasmic or bifunc-
tional enzyme have been implicated in dominant, axonal Charcot-
Marie-Tooth disease (Antonellis et al., 2003; Jordanova et al., 2006;
Latour et al., 2010; Tsai et al., 2017; Vester et al., 2012). Importantly,
for the recessive diseases associated with ARS mutations, the inheri-
tance patterns, nature of the mutations, functional studies, and signif-
icant phenotypic overlap associated with each locus all point to a loss-
of-functionmechanism (Meyer-Schuman &Antonellis, 2017; Oprescu,
Griffin, Beg, & Antonellis, 2017).
The charging of tRNA molecules with phenylalanine in the cyto-
plasm is accomplished via a tetrameric enzyme that contains two
catalytic subunits encoded by phenylalanyl-tRNA synthetase alpha
(FARSA; MIM# 602918) and two regulatory subunits encoded by
phenylalanyl-tRNA synthetase beta (FARSB; MIM# 609690) (Rodova,
Ankilova, & Safro, 1999). To date, no variants in FARSA or FARSB
have been implicated in human disease; however, loss-of-function
mutations in the gene encoding mitochondrial phenylalanyl-tRNA
synthetase (FARS2) have been implicated in recessive phenotypes
including hereditary spastic paraplegia, Alpers syndrome, early onset
epilepsy, global delay, dysarthria, and tremor (Almalki et al., 2014; Cho
et al., 2017; Elo et al., 2012; Raviglione et al., 2016; Shamseldin et al.,
2012; Vernon, McClellan, Batista, & Naidu, 2015; Walker et al., 2016;
Yanget al., 2015).Here,wedescribe apatientwith a severe, lethal,mul-
tisystem, developmental phenotype associated with compound het-
erozygosity for loss-of-function FARSB variants. Consentwas obtained
for this research, which was approved by the Institutional Review
Board of the University ofMichigan.
The male proband was born to a 31-year-old G2P0 mother at 35
and 4/7 weeks gestation and had a history of intrauterine growth
restriction and oligohydramnios; his parents are nonconsanguineous.
The family history was significant for a previous pregnancy loss at
37 weeks secondary to placental abruption. The proband was deliv-
ered by urgent cesarean section due to recurrent fetal heart rate with
variable (and a few prolonged) decelerations. Apgar scores were 8 and
9 at 1 and 5 min, respectively. Birth weight was 1.927 kg (2%); length
was 44 cm (8%); and head circumference was 32 cm (31%). Grunt-
ing was noted 10 min after birth, but with normal oximetry, and then
recurred once at 5 hr after birth and resolved. The proband passed his
newborn hearing andmetabolic screens and pre- and post-ductal pulse
oximetry. Physical examinations, other than being small for gestation
age, were normal. He developed mild indirect hyperbilirubinemia on
day of life 2 that responded to phototherapy appropriately. He was
discharged home and was initially bottle fed to gain weight, but was
transitioned to breast feeding. He had frequent emesis greater than
20min after feeds.
At 5 months (4 months corrected), his pediatrician referred him
back to the University of Michigan for evaluation of failure to thrive,
developmental delay, left inguinal hernia, tachypnea, and a chronic
cough since birth occurring throughout the day and night. He was hos-
pitalized for 2 months. Growth parameters had moved below the 3rd
centile for weight and length and to 5th–10th centile for head circum-
ference. Resting heart rate was in the 130 sec and he had baseline
tachypnea (respiratory rate in the 70 sec). Physical examination was
significant for sunken eyes, prominent cheeks, high palate, increased
range of motion of joints, truncal hypotonia with marked head lag
on pull to sit, and a small scrotum and phallus. Because of respira-
tory distress, he was transferred to the pediatric intensive care unit,
where he required intubation for 4 days. Chest radiograph showed
diffuse patchy airspace opacities with peribronchial cuffing. Multiple
medical problems were identified including gastroesophageal reflux
disease, profound vitamin D and A deficiency, severe hypocalcemia
(requiring, at times, continuous calcium infusion up to 25 mg/kg/hr
to maintain ionized calcium ≥ 1.2), supplementation with ergocalcif-
erol or cholecalciferol, and hypoalbuminemia (albumin 2.4, protein 3.9)
with anasarca and ascites, hungry bone syndromewith osteopenia and
rickets, elevated liver transaminases (AST:100–300; ALT:80–150) and
cholestasis (total bilirubin 3–4; direct bilirubin 2–3), yet normal INR.
He had a nonanion gap metabolic acidosis, which resolved. CPK was
46, iron 39, ferritin 23.3, alpha-1-antitrypsin 173, and ceruloplasmin
and cystic fibrosis sweat testing were normal. Numerous problems
ensued during this hospitalization. He developed urinary tract infec-
tions with Enterobacter cloacae and Enterococcus feacalis, and had a nor-
mal VCUG. He also developed Candida parapsilosis bacteremia from his
PICC line. He subsequently developed a DVT in the axillary vein above
the PICC line. He had a seizure presumed secondary to hypoglycemia
andhypocalcemia. Echocardiogramswereperformedonmultiple occa-
sions and revealed normal cardiac anatomy and good systolic function.
Abdominal ultrasound revealed asciteswithout portal hypertension, as
well as diffuse and increased parenchymal echogenicity suggestive of
hepatocellular disease, and diffusely increased echogenicity of the kid-
neys, suggestive of renal disease. His abdominal distension improved
after albumin infusion and he required diuretics for fluid overload. He
did not have diarrhea and he had normal stool alpha-1-antitrypsin and
stool elastase. He required post-pyloric tube feeds. Due to anemia and
pancytopenia, a bone marrow biopsy was performed and flow cytom-
etry was normal. He had a normal swallow study. MRI of the abdomen
revealed hepatic steatosis but no increased liver iron. Hepatitis viral
serologies were negative. Head ultrasound identified possible abnor-
mal periventricularwhitematter and bilateral basal ganglia echogenic-
ity, and follow-up brain MRI at 5 months corrected age, showed
cerebral volume loss and incomplete closure of the Sylvian fissures
(Figure 1A and B); MR spectroscopy showed no lactate peak. Myelina-
tion was appropriate for age given his prematurity. He had an episode
of dysconjugate gaze and abnormal tracking eye movements and was
found to have hypoglycemia to 37mg/dl after being fasted for 2.5 hr in
preparation for a fasting blood specimen; at that timeheadCTandMRI
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F IGURE 1 HeadMRI, liver pathology, and chestCTof theproband.A
and B: Coronal and sagittal T1-weighted headMRI images obtained at
5 months corrected age showing incomplete closure of the Sylvian fis-
sures (asterisk in A), and bilateral frontoparietal cerebral volume loss
(asterisk in B). C–F: Liver pathology. Architectural distortion (4×) with
nodular formation (C); portal chronic inflammationwith focal steatosis
(10×) (D); Masson trichrome stain (2×) with well-developed cirrhosis
and bridging fibrosis (E); andCK7 immunostain (4×) showing extensive
bile ductular reaction (F).G andH: Chest CT (18months) showing sub-
pleural cystic changes (arrows) and interstitial disease
were nonspecific. One week later, he had a seizure-like event with left
upward eye gaze and symmetric jerking of all extremities associated
with ionized calciumof 0.88mmol/l, which responded to supplementa-
tion. He developed worsening tachypnea with increasing ascites, usu-
ally associated with hypoalbuminemia (a chronic problem during and
after this hospitalization). After extubation, he was placed on CPAP
and thenweaned to high flow nasal cannula and then room air over the
course of a week. He remained intermittently tachypneic. He was dis-
charged after 2 months (corrected age 6 months) and had a heart rate
of 150–160 per minute, respiratory rate of ∼40 per minute, discharge
weight 4.86 kg (≪ 3%; 50% for a 1.5 month old), length 60 cm (<3%;
50% for a 2.75month old), and head circumference 42 cm (10%).
Interstitial pulmonary disease, liver cirrhosis (hypoalbuminemia),
and portal hypertension with ascites, esophageal varices with GI
bleeding, developmental delay, and failure to thrive continued to be
problems. G-tube placement and percutaneous left lobe liver biopsy
were performed at 14 months. The liver parenchyma showed archi-
tectural distortion with nodular formation and bridging fibrosis by
trichrome (Figure 1C and E). Focal mild steatosis was observed
(Figure 1D). CK7 immunostaining revealed bile ductular proliferation
(Figure 1F). Moderate chronic portal inflammatory infiltrates were
noted with neutrophils associated with the ductular reaction. There
is was patchy intrahepatocyte cholestasis, without significant intra-
canalicular cholestasis or bile plugging. No clear lobular hepatitic pat-
tern or interface activity (such as plasma cells at the limiting plate) was
appreciated. Iron stain was negative. There were no viral cytopathic
effects identified. The overall findings were consistent with well-
established cirrhosis of unknown etiology. Electron microscopy (Supp.
Figure S1)was performed and hepatocytes showed reactive expansion
of smooth ER, focal cystic dilation of rough ER containing sparse del-
icate material of no specific appearance, focal accumulation of glyco-
gen granules, common autophagic bodies, bulky accumulations of non-
membrane bound material consistent with bile residue in hepatocyte
cytoplasm, and universally normal appearingmitochondria.Many hep-
atocytes contained abundant microvesicular lipid that appeared to be
nonmembrane bound and thus free in the cytoplasm. No abnormal
storage of material was identified within the lysosomes or cytoplasm.
Chest CT at 1.5 years and chest radiographs at 22 months, showed
subpleural cystic changes in the bilateral lungs consistent with
interstitial lung disease (Figure 1G and H). Bronchoscopy showed
only moderate dynamic collapse in the left main stem and lingual
regions; milder collapse in the LLL segments. Bronchoalveolar lavage
was negative for alveolar proteinosis and malignancy. Because of
the pulmonary findings, a left nasal brushing biopsy was performed
and showed motile cilia, and electron microscopy revealed normal
respiratory ciliary ultrastructure. He was found to have pulmonary
hypertension at 22 months at the time of an acute respiratory exac-
erbation requiring high frequency oscillatory ventilation, milrinone,
and inhaled nitrous oxide. At that time, he had a normal bubble study
negative for hepatopulmonary syndrome and normal biventricular
function. He developed a subacute DVT in the distal external iliac
and common femoral veins and was anticoagulated. He developed a
right-sided intraparenchymal brain hemorrhage, presumed secondary
to lovenox therapy. He received a ventriculostomy at 23 months; con-
tinued bleeding was noticed in the right parietal region. He developed
hydrocephalus, which worsened with intraparenchymal hemorrhage
and ultimately received a VP shunt at 24months.
Medical Genetics consultation revealed normal results for N-
glycan and O-glycan profiles, CPK, lysosomal enzymes including
acid maltase, quantitative plasma and CSF amino acids, very long
chain fatty acids, acylcarnitine profiles, SNP-based chromosomal
microarray, methylation PCR for Prader-Willi/Angelman syndromes,
7-dehydrocholesterol, and ATP7A (MIM# 300011) sequencing.
Urine organic acid analysis revealed 4-hydroxyphenylacetic, 4-
hydroxyphenylactic, and 4-hydroxyphenylpyruvate, consistent with
liver dysfunction. Right thigh skeletal muscle biopsy by standard his-
tological analysis showed nonspecific findings with slightly increased
lipid droplets within fibers. Transmission electron microscopy showed
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nonspecific, mild mitochondrial and myofibrillar irregularities. Mus-
cle mitochondrial electron transport chain (ETC) enzyme analysis
demonstrated increased citrate synthase (CS) control enzyme activity,
with deficiency (15% of control after normalization for CS activity) of
rotenone sensitive complex I+ III activity, fulfilling onemajormodified
Walker criterion for the diagnosis of a respiratory chain disorder.
Several other ETC activities were reduced with relative preservation
of complex II. Venous and arterial lactate wasmeasuredmultiple times
and was not consistently elevated. Because of the enzyme deficien-
cies noted, a 164 nuclear gene and mitochondrial next-generation
sequencing panel was obtained at 24 months. This analysis revealed
heterozygosity for a maternally inherited NDUFS2 (MIM# 602985)
variant of uncertain significance (VUS), p.H380D (a variant with a
frequency of 0.15% in the NHLBI ESP and 0.06% in ExAC, with no
homozygotes), and hemizygosity for a maternally inherited PHKA2
(MIM# 300798) VUS, p.L413S (not seen in ESP; 0.008% in ExAC with
5 hemizygotes) (Lek et al., 2016). No second variant was identified in
NDUFS2, which would be required to consider this recessive disorder
(Loeffen et al., 2001). PHKA2 deficiency is unlikely as there was no
liver glycogenosis observed on biopsy and the other clinical features
of the proband are much more severe than typical patients with
this disorder (Hendrickx et al., 1995). Thus, neither the NDUFS2 nor
PHKA2 variants accounted for the severe clinical manifestations of the
proband, who was readmitted multiple times for respiratory failure
and hypoalbuminemia requiring intensive care, and passed away at
32months. No autopsy was obtained.
To further explore thegenetic underpinningsof thephenotype iden-
tified in our proband, we performed whole-exome sequencing (WES)
analysis on DNA isolated from blood from the proband and his unaf-
fected parents. TrioWES studies performed at GeneDx (Gaithersburg,
MD) revealed the aforementioned maternally inherited variants of
unknown significance inNDUFS2 and PHKA2. The only other candidate
pathogenic variants identified in these studies thatmet the inheritance
pattern andallele frequency criteriawere twovariants of unknownsig-
nificance in FARSB: c.767C>T,which predicts a p.Thr256Metmissense
variant; and c.1486delCinsAA, which predicts a p.His496Lysfs*14
protein-truncating or null allele. The unaffected father is heterozy-
gous for p.Thr256Met, the unaffected mother is heterozygous for
p.His496Lysfs*14, and the proband was compound heterozygous for
both FARSB variants (Figure 2A). Please note that these variants are
annotated on NM_005687.4 and each was validated using Mutalyzer
(https://mutalyzer.nl). The variants and associated phenotype have
been submitted to ClinVar (https://www.ncbi.nlm.nih.gov/clinvar/):
p.Thr256Met accession no. SCV000676382; p.His496Lysfs*14 acces-
sion no. SCV000676381.
Examination of each FARSB variant on the genome aggregate
database browser (gnomAD; https://gnomad.broadinstitute.org) (Lek
et al., 2016) revealed the presence of p.Thr256Met FARSB at a very low
frequency (12 out of 276,122 alleles with no homozygous individuals)
and the absence of p.His496Lysfs*14 FARSB. While p.His496Lysfs*14
FARSB is very likely to result in a null allele or a nonfunctional pro-
tein, the importance of p.Thr256 in enzyme function is less clear.
Multiple-species conservation analysis revealed that p.Thr256 is
conserved among diverse species ranging from human to yeast (Fig-
F IGURE 2 Characterization of the FARSB variants identified in the
proband. A: A simplex pedigree is shown with squares representing
males and circles representing females. Genotypes are indicated under
each symbol for the father, mother, and male proband (filled square).
The proband is the only affected individual in the pedigree. B: The
position of the p.Thr256Met variant is shown along with surround-
ing amino acid sequences for multiple, evolutionarily diverse species.
Species are indicated along the left and the position of the affected
residue is indicated by an arrow and bold text. C: Western blot anal-
yses were performed using total protein lysates from fibroblasts iso-
lated from two control individuals and from the patient described in
this study, the latter performed in duplicate (Sample 1 and Sample 2).
An anti-FARSB or anti-eIF2𝛼 antibody was employed to test for the
effect of the FARSB variants on protein levels and to control for pro-
tein loading, respectively. Sample names are provided across the top of
the panel and sizes in kDa are indicated on the right.D: Similarwestern
blot analyses as described in panel C using an anti-FARSA antibody. In
panelsC andD, the ratio of FARSB or FARSA to eIF2𝛼 was determined
bydividing theoptical density of eachFARS-specific bandby that of the
corresponding eIF2𝛼-specific band
ure 2B). Furthermore, resolving the structure of human cytoplasmic
phenylalanyl-tRNA synthetase revealed that threonine 256 resides in
the editing domain and mutating this residue to alanine reduces the
ability to distinguish between tyrosine and phenylalanine, resulting in
enzyme mischarging (Finarov, Moor, Kessler, Klipcan, & Safro, 2010;
Sasaki et al., 2006).
Since p.His496Lysfs*14 FARSB causes a frameshift mutation that
leads to a premature stop codon, the variant is predicted to ablate
the expression of full-length FARSB, which would predict a ∼50%
decrease in full-length protein levels in patient cells. To address this,
we performed western blot analysis on proteins isolated from cul-
tured patient fibroblasts and two control fibroblast lines (i.e., from
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individuals without FARSB variants). Briefly, protein samples (20 𝜇g
per sample) were subjected to electrophoresis, transferred onto a
PVDFmembrane, and incubatedwith an anti-FARSB antibody (Sigma–
Aldrich, St. Louis,MO;HPA061398) or ananti-eIF2𝛼 antibody (Cell Sig-
naling Technology, Danvers, MA; 9722) to control for protein loading.
Interestingly, our results revealed a dramatic reduction of full-length
FARSB protein levels (∼97% reduction) in patient fibroblast cells com-
pared to control cell lines (Figure 2C). Since FARSB forms an 𝛼2𝛽2
hetero-tetramer with FARSA (Rodova et al., 1999), we hypothesized
that severely reduced FARSB levelsmay destabilize and reduce FARSA
levels. To address this, we performed the same western blot analyses
described above using an antibody designed against FARSA (Sigma–
Aldrich, St. Louis, MO; HPA001911). These analyses revealed a signif-
icant decrease in FARSA levels (∼66% reduction) in patient cells com-
pared to the control cell lines (Figure 2D).
The observation of dramatically reduced FARSB protein levels in
patient cells requires further consideration of the p.Thr256Met FARSB
missense variant. We computationally predicted the pathogenicity of
this variant using CADD (Kircher et al., 2014), PolyPhen2 (Adzhubei
et al., 2010), and MUPro (Cheng, Randall, & Baldi, 2006), and all three
algorithms provided a prediction of “pathogenic”: CADD score = 33;
PolyPhen2 score = 1; and MUPro score = −0.4315118. Importantly,
MUPro scores that are less than 0 predict a decrease in protein stabil-
ity that is consistentwith ourwestern blot analyses. Thus, even though
p.Thr256Met FARSB resides in the editing domain (see above), this vari-
ant likely impacts protein stability that would result in reduced tRNA
charging. Indeed, the lack of a phenotype in the father that carries
p.Thr256Met FARSB and previous reports showing that Chinese ham-
ster ovary cells are tolerant of misincorporations of phenylalanine for
tyrosine (Raina et al., 2014) indicate that altered editing is not likely
to be responsible for the phenotype observed in the proband. We
therefore conclude that compound heterozygosity for p.Thr256Met
and p.His496Lysfs*14 FARSB results in a severe reduction of FARSB
protein levels that causes a downstream reduction in FARSA lev-
els. These reduced protein levels likely result in a severe reduction
in phenylalanyl-tRNA synthetase activity that is responsible for the
observed recessive disease phenotype in our patient. In support of
this notion, we are aware of another family with two affected siblings,
both with novel, bi-allelic FARSB variants including a predicted loss-of-
function variant and apredicteddeleteriousmissense variant, and very
similar clinical features (Wendy Chung, personal communication).
A detailed comparison of the phenotypes of our proband (described
above) and the phenotypes of previously reported patients with
ARS-associated recessive disease (Meyer-Schuman & Antonellis,
2017) revealed striking overlap (Supp. Table S1). For example, the
following phenotypes that we observed in our patient have been
reported in patients with other ARS-associated recessive syndromes:
(1) intrauterine growth restriction in patients with AARS (MIM#
601065), GARS (MIM# 600287), IARS (MIM# 600709), MARS (MIM#
156560),MARS2 (MIM# 609728),QARS (MIM# 603727),VARS (MIM#
192150), and YARS2 (MIM# 610957) variants; (2) failure to thrive in
patients with AARS, AARS2 (MIM# 612035), CARS2 (MIM# 612800),
EARS2 (MIM# 612799), IARS, LARS (MIM# 151350), MARS, MARS2,
SARS2 (MIM# 612804), YARS (MIM# 603623), and YARS2 variants; (3)
developmental delay in patients with AARS, FARS2 (MIM# 611592),
GARS, IARS, KARS (MIM# 601421), LARS,MARS,MARS2,NARS2 (MIM#
612803), PARS2 (MIM# 612036), QARS, RARS2 (MIM# 611524),
SARS2, VARS, and YARS variants; (4) hypotonia in patients with CARS2,
EARS2, HARS2 (MIM# 600783), IARS, KARS, LARS, MARS, MARS2,
QARS, RARS (MIM# 107820), RARS2, SARS2, TARS2 (MIM# 612805),
and YARS variants; (5) abnormal or decreased white matter in patients
with AARS, CARS2, DARS (MIM# 603084), DARS2 (MIM# 610956),
EARS2, GARS, IARS, KARS, MARS2, NARS2, QARS, RARS, RARS2, and
YARS variants; and (6) liver dysfunction in patients with EARS2, FARS2,
IARS, LARS, LARS2 (MIM# 604544),MARS, and YARS variants.
In addition to the overlap with individual features of other ARS-
related recessive syndromes, the phenotype of our patient displayed
remarkable overlap with features previously associated with homozy-
gosity or compound heterozygosity for loss-of-function methionyl-
tRNA synthetase (MARS) variants including: intrauterine growth
restriction; failure to thrive; developmental delay; inguinal hernia;
hypotonia; recurrent infections; interstitial lung disease; and liver dys-
function (vanMeel et al., 2013;Hadchouel et al., 2015; Sunet al., 2017).
Similarly, our patient shared many clinical features previously asso-
ciated with homozygosity or compound heterozygosity for loss-of-
function tyrosyl-tRNA synthetase (YARS) variants including: intrauter-
ine growth restriction; failure to thrive; developmental delay; eme-
sis; deep-set eyes; prominent cheeks; high palate; joint hypermobility;
hypotonia; abnormal white matter; and liver dysfunction (Nowaczyk
et al., 2017; Tracewska-Siemiątkowska et al., 2017). Importantly, the
phenotypic overlap betweenour patient andother patientswith reces-
sive ARS-related diseases strongly supports the pathogenicity of the
FARSB variants reported here. Furthermore, this phenotypic overlap
also indicates that the mutations have a direct effect on the primary
function of the enzyme: charging tRNA with phenylalanine for pro-
tein translation. In support of this latter notion, many of the clini-
cal manifestations reported here have been associated with muta-
tions that disrupt the cytoplasmic or mitochondrial protein transla-
tional machinery (Scheper, van der Knaap, & Proud, 2007), including
liver dysfunction—arguably the most severe phenotype observed in
our patient—associated with EIF2AK3 (MIM# 604032), GFM1 (MIM#
606639), TUFM (MIM# 602389), andGCN2 (MIM# 609280) perturba-
tions (Coenen et al., 2004; Delépine et al., 2000; Guo &Cavener, 2007;
Valente et al., 2007).
In summary, we describe clinical, genetic, and functional data that
implicate FARSB mutations in a severe, lethal, multisystem, recessive,
and developmental phenotype. These data warrant careful assess-
ments for loss-of-function FARSB–or FARSA–variants in patients with
a similar clinical syndrome, especially when liver dysfunction is
described.Our studyexpands the locusheterogeneityofdiseases asso-
ciatedwithARSs (Meyer-Schuman&Antonellis, 2017) and emphasizes
the importance of detailed clinical comparisons and relevant func-
tional studies when implicating ARS variants in disease pathogenesis
(Oprescu et al., 2017).
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